EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage

Keishi Ouchi, Masashi Ninomiya iD, Mio Tsuruoka iD, Jun Inoue iD, Atsushi Hiraoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Takayoshi Oikawa iD, Kei Endo iD, Tamami Abe iD und 11 weitere

Journal of Gastroenterology and Hepatology · 2026-11 · 41 (11) · 3567-3574

DOI: 10.1111/jgh.70765 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 28.09.2026. Verfasst von Keishi Ouchi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Tohoku University Hospital, Sendai, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim The optimal treatment strategy for patients with intermediate‐stage hepatocellular carcinoma beyond the up‐to‐seven criteria (Barcelona Clinic Liver Cancer B2) remains uncertain. Although transarterial chemoembolization has long been the standard of care, its efficacy is limited in this subgroup, and systemic therapies have recently been introduced. We aimed to explore treatment modalities associated with survival beyond that predicted by a previously validated prognostic model.

Methods

We retrospectively analyzed 113 patients diagnosed with BCLC‐B2 stage hepatocellular carcinoma between 2017 and 2024. Predicted survival was calculated using a previously established prognostic model, and treatment benefits were evaluated by comparing observed survival with predicted outcomes. Logistic and linear regression analyses were performed to identify factors associated with survival gain.

Results

The median observed survival was 26.0 months, compared with a model‐predicted survival of 24.7 months. Treatment with atezolizumab plus bevacizumab was significantly associated with survival exceeding model predictions (odds ratio: 3.77, p = 0.0065). Linear regression analysis confirmed that atezolizumab plus bevacizumab was independently associated with a greater survival benefit (β = 0.192, p = 0.0084). Subgroup analysis demonstrated that this association was particularly pronounced in patients with high tumor burden (tumor number plus size ≥ 11), whereas no significant associations were observed for lenvatinib, STRIDE, or cabozantinib.

Conclusions

Atezolizumab plus bevacizumab was associated with survival beyond that predicted by a prognostic model in patients with BCLC‐B2 stage hepatocellular carcinoma, particularly those with high tumor burden. These findings should be considered exploratory and associative rather than evidence of a causal treatment effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBevacizumabAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesNeoplasm StagingMaleTreatment OutcomeMiddle AgedAgedPrognosisSurvival Rate

Stichwörter der Autor:innen

Barcelona Clinic Liver Cancer B2 stageatezolizumab plus bevacizumabhepatocellular carcinomathe efficacy of chemotherapy

Substanzen

BevacizumabAntibodies, Monoclonal, Humanizedatezolizumab

Autor:innen und Institutionen

  • Division of Gastroenterology, Tohoku University Hospital, Sendai, Japan.
  • Institute for Excellence in Higher Education, Tohoku University, Sendai, Japan.
  • Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Shiwa, Iwate, Japan.
  • Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Department of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata, Japan.

ORCID-Profile: Masashi Ninomiya, Mio Tsuruoka, Jun Inoue, Takayoshi Oikawa, Kei Endo, Tamami Abe, Kazumichi Abe, Wataru Sato, Hiroshi Numao, Hidekatsu Kuroda, Yoshiyuki Ueno

Zitieren

APA

Ouchi, K., Ninomiya, M., Tsuruoka, M., Inoue, J., Hiraoka, A., Sato, K., Doi, K., Watanabe, K., Sasazaki, T., Oikawa, T., Endo, K., Abe, T., Fujita, M., Abe, K., Katsumi, T., Sato, W., Iino, C., Tanabe, N., Numao, H., …, & Masamune, A. (2026). Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage. Journal of Gastroenterology and Hepatology, 41(11), 3567-3574. https://doi.org/10.1111/jgh.70765

Vancouver

Ouchi K, Ninomiya M, Tsuruoka M, Inoue J, Hiraoka A, Sato K, et al. Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage. Journal of Gastroenterology and Hepatology. 2026;41(11):3567-3574. doi:10.1111/jgh.70765

BibTeX
@article{Ouchi2026,
  author = {Ouchi, Keishi and Ninomiya, Masashi and Tsuruoka, Mio and Inoue, Jun and Hiraoka, Atsushi and Sato, Kosuke and Doi, Kotaro and Watanabe, Kengo and Sasazaki, Tomoya and Oikawa, Takayoshi and Endo, Kei and Abe, Tamami and Fujita, Masashi and Abe, Kazumichi and Katsumi, Tomohiro and Sato, Wataru and Iino, Chikara and Tanabe, Nobukazu and Numao, Hiroshi and Ohira, Hiromasa and Kuroda, Hidekatsu and Ueno, Yoshiyuki and Masamune, Atsushi},
  title = {Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  volume = {41},
  number = {11},
  pages = {3567--3574},
  doi = {10.1111/jgh.70765}
}
Kostenlos starten →